Cizzle Biotechnology New Research Agreement with the University of York for Cancer Tests

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, is pleased to announce that it has entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.

The Company’s wholly owned subsidiary Cizzle Biotechnology Limited was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley. The new agreement extends that relationship and provides seconded staff and access to the University’s state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation (CRO) partner Fairjouney Biologics.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: “We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world’s premier institutions for inspirational and life-changing research.  This new agreement will provide valuable additional resource and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer.”

You might also enjoy reading  Cizzle Biotechnology expands in the USA with new collaboration agreements

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index